drugset
drugset / Trial / NCT00983346

Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients

NCT00983346 ↗

Phase 2 Terminated 17 enrolled University of Utah Millennium Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelPrevention

Summary

OBJECTIVES * Primary: To evaluate the bone anabolic effect of bortezomib in patients with smoldering myeloma. * Secondary: To evaluate the effect of bortezomib on the natural history of smoldering myeloma.

Timeline

Start
2009-10
Primary completion
2014-09
Completion
2014-09

Outcome

Outcome not reported

Stopped (Enrollment): “Lab Staff that was required left the institution, therefore accrual closed prematurely”

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule 0.7 mg/m2 Intravenous

Indications

plasma cell myeloma